A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Brief description of study
This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine to participants with colorectal cancer.
Clinical Study Identifier: s22-01548
ClinicalTrials.gov Identifier: NCT05609370
Principal Investigator:
Kristen Spencer.
Other Investigators:
Laura Palazzolo,
Paul E. Oberstein,
Michael Shusterman,
Anam Qureshi,
Marta Wioleta Wronska,
Carol M Lee,
Jonathan B Kahn,
Monica Rivera,
Keriann M Scavone,
Nitish Mehta,
Nina Beri,
Jennifer Chuy,
Anastasiya Apanasyuk,
Rafael Winograd,
Daniel J Becker,
Shun Yu,
Alexander A Hindenburg.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.